Register to get unlimited Level 2

Motif Bio inks deal for toxoplasmosis study in Germany

By Josh White

Date: Wednesday 22 May 2019

Motif Bio inks deal for toxoplasmosis study in Germany

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating 'iclaprim' in an in vitro model of ocular toxoplasmosis, it announced on Wednesday.
The AIM-traded firm said the research would focus on toxoplasma chorioretinitis - an orphan disease that is a type of ocular toxoplasmosis, which is a parasitic disease that could result in severe life-threatening infections or blindness.

It said the work would be led by professor Dr Ildiko Rita Dunay, director of the Institute of Inflammation and Neurodegeneration at the university.

"We are very pleased to work with Dr Dunay, who is an expert in the area of toxoplasmosis," said Motif Bio's chief medical officer Dr David Huang.

"In vitro data indicate that iclaprim has activity against toxoplasma.

"The data generated from Dr Dunay's lab will be important in understanding whether iclaprim can play a role in this potentially devastating, progressive and recurring necrotizing retinitis, including vision-threatening complications."


Email this article to a friend

or share it with one of these popular networks:

Top of Page